Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Equity (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Return on Equity data on record, last reported at 0.19% in Q4 2025.

  • For Q4 2025, Return on Equity rose 30.0% year-over-year to 0.19%; the TTM value through Dec 2025 reached 0.19%, up 30.0%, while the annual FY2025 figure was 0.23%, 31.0% up from the prior year.
  • Return on Equity reached 0.19% in Q4 2025 per TARS's latest filing, up from 0.24% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.02% in Q2 2021 and bottomed at 0.66% in Q4 2023.
  • Average Return on Equity over 5 years is 0.34%, with a median of 0.31% recorded in 2022.
  • Peak YoY movement for Return on Equity: tumbled -35bps in 2023, then increased 30bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.07% in 2021, then crashed by -345bps to 0.31% in 2022, then crashed by -112bps to 0.66% in 2023, then rose by 26bps to 0.49% in 2024, then soared by 61bps to 0.19% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.19% in Q4 2025, 0.24% in Q3 2025, and 0.27% in Q2 2025.